List of Excipients in Branded Drug LEVETIRACETAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WG Critical Care LLC	LEVETIRACETAM	levetiracetam	44567-500	ACETIC ACID
WG Critical Care LLC	LEVETIRACETAM	levetiracetam	44567-500	SODIUM ACETATE
WG Critical Care LLC	LEVETIRACETAM	levetiracetam	44567-500	SODIUM CHLORIDE
WG Critical Care LLC	LEVETIRACETAM	levetiracetam	44567-500	WATER

Generic Drugs Containing LEVETIRACETAM

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	levetiracetam	0121-0799	ACESULFAME POTASSIUM
PAI Holdings LLC dba PAI Pharma	levetiracetam	0121-0799	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	levetiracetam	0121-0799	GLYCERIN
PAI Holdings LLC dba PAI Pharma	levetiracetam	0121-0799	MALTITOL

What are the Most Frequently-Used Excipients in LEVETIRACETAM?

# Of NDCs	Excipient
49	ACESULFAME POTASSIUM
35	ACETIC ACID
2	ALCOHOL
1	ALUMINUM OXIDE

Levetiracetam Excipient Strategy and Commercial Opportunities

Last updated: July 31, 2026

Levetiracetam is a mature, high-volume generic antiepileptic with limited conventional API differentiation. Commercial opportunity is concentrated in excipient optimization for oral liquids, pediatric dosing, modified-release tablets, injection products, taste masking, supply-chain resilience, and specialty presentations. The original branded product, Keppra, has lost market exclusivity, and the U.S. market has extensive generic competition. New value is more likely to come from formulation performance, patient usability, manufacturing efficiency, and regulatory execution than from broad composition-of-matter patent protection.

What dosage forms and excipients are used in levetiracetam products?

Levetiracetam is marketed as immediate-release tablets, oral solution, oral suspension or liquid products, extended-release tablets, and intravenous injection. Each form creates a different excipient strategy.

Immediate-release tablets

The reference Keppra immediate-release tablets use a conventional direct-compression or granulation platform. Label-reported excipients include:

Excipient category	Typical function in levetiracetam tablets
Croscarmellose sodium	Superdisintegrant
Corn starch	Binder, filler, disintegrant
Colloidal silicon dioxide	Glidant
Magnesium stearate	Lubricant
Polyethylene glycol 3350	Film-coating component
Polyvinyl alcohol	Film former
Talc	Anti-tacking agent and coating aid
Titanium dioxide	Opacifier and colorant

The tablet formulation is technically mature. Generic manufacturers can generally use standard excipient systems without a material performance barrier, provided that dissolution, assay, content uniformity, stability, and bioequivalence requirements are met. The main development opportunities are lower-cost processing, reduced tablet size, improved coating robustness, and differentiation for patients with swallowing difficulty.

Oral solution

Keppra oral solution is a higher-value excipient target because taste, microbial control, chemical stability, and pediatric acceptability directly affect product use. Label-reported ingredients include:

• Sodium citrate dihydrate
• Citric acid monohydrate
• Methylparaben
• Propylparaben
• Glycerin
• Maltitol
• Ammonium glycyrrhizate
• Artificial grape flavor
• Purified water

The formulation uses a buffered aqueous system with parabens for preservation and polyol-based sweetening. Maltitol and glycerin contribute sweetness and mouthfeel while limiting reliance on sucrose. Ammonium glycyrrhizate provides intense sweetness and flavor modulation.

Commercially relevant formulation work includes:

• Reducing bitterness and metallic aftertaste
• Improving flavor persistence
• Replacing parabens where market or customer requirements favor alternative preservatives
• Developing sugar-free and low-cariogenic systems
• Reducing viscosity while maintaining palatability
• Improving dose accuracy in oral syringes
• Creating single-dose sachets or ready-to-administer liquid presentations
• Improving stability after opening
• Developing alcohol-free, allergen-controlled, and clean-label variants

Extended-release tablets

Levetiracetam extended-release tablets require a controlled-release matrix or coating system. The reference formulation uses hydrophilic polymer technology, with excipients such as hydroxypropyl cellulose, hypromellose, polyethylene glycol, talc, and titanium dioxide reported in product labeling.

Extended-release formulation is more sensitive than immediate-release development. The excipient system controls:

• Hydration and gel-layer formation
• Drug diffusion
• Tablet erosion
• Dose dumping risk
• Food effect
• Alcohol sensitivity
• Release profile across the gastrointestinal tract

A generic extended-release product must demonstrate both pharmaceutical equivalence and bioequivalence. Small changes in polymer grade, viscosity, particle size, compression force, or coating weight can change the release profile. Excipient suppliers with controlled polymer grades, reproducible particle-size distributions, and strong documentation have a stronger commercial position in this segment.

Intravenous injection

The intravenous product is an aqueous solution containing levetiracetam with a relatively simple excipient system. Label-reported components include sodium chloride, sodium acetate trihydrate, glacial acetic acid, and water for injection.

The formulation priorities are different from oral products:

• Low particulate burden
• Sterility assurance
• Low endotoxin levels
• Container-closure compatibility
• pH control
• Osmolality
• Short-term dilution stability
• Compatibility with common infusion fluids and administration sets

The injection product has fewer excipient components but higher manufacturing and quality requirements. Opportunities include ready-to-use bags, premixed infusion containers, lower-volume presentations, and packaging systems that reduce preparation time in hospitals.

What excipient functions matter most in levetiracetam products?

The most commercially important excipient functions are taste masking, controlled release, preservation, tablet manufacturability, and patient administration.

Product issue	Relevant excipient strategy	Commercial value
Bitter oral liquid	Sweetener, flavor, bitterness blocker, viscosity modifier	Pediatric and geriatric adherence
Tablet friability	Binder, compression aid, coating system	Lower manufacturing loss
Slow dissolution	Superdisintegrant, wetting agent, particle engineering	Bioequivalence and batch consistency
Extended release	Hypromellose or other matrix polymer	Once-daily dosing
Microbial control	Preservative, pH control, packaging	Multi-dose liquid stability
Injection stability	Buffer, tonicity agent, container system	Hospital readiness
Swallowing difficulty	Smaller tablet, dispersible system, oral liquid	Broader patient usability
Supply risk	Dual-source excipients and regional qualification	Continuity of supply

What commercial opportunities exist in levetiracetam excipients?

Pediatric and geriatric oral liquids

The most accessible formulation opportunity is an improved oral liquid. Levetiracetam is widely used in children, where taste, dosing flexibility, and administration volume influence adherence. Older patients and patients with dysphagia also benefit from liquid presentations.

A differentiated product could use:

• A lower-volume concentrated solution
• A more acceptable flavor system
• A suspension with improved redispersibility
• A preservative-free unit-dose format
• A multidose bottle with an integrated oral syringe
• A formulation compatible with feeding tubes
• A formulation with reduced foaming and less residue in administration devices

A concentrated product creates a tradeoff. Lower volume improves administration but increases the importance of dose-measurement accuracy, local irritation assessment, and safety controls against tenfold dosing errors.

Taste-masking platforms

Levetiracetam’s bitterness creates a potential platform opportunity for excipient suppliers and specialty generic companies. Taste masking can use:

• Ion-exchange resins
• Polymer coating of drug particles
• Lipid or wax barriers
• Cyclodextrins
• Amino-acid or salt-based bitterness modifiers
• Multi-layer flavor systems
• pH and sweetness optimization

A taste-masked multiparticulate product could support sprinkle administration over soft food or enteral nutrition. Such a product would require control of dose uniformity, release behavior, food compatibility, and stability after opening.

Taste masking is commercially stronger when linked to a defined delivery advantage. A flavor change alone may be difficult to defend or price. A pediatric sprinkle product, feeding-tube product, or single-dose sachet has a clearer market proposition.

Modified-release polymer systems

Levetiracetam extended-release tablets provide an opportunity for polymer suppliers and generic developers with expertise in hydrophilic matrices. The technical focus is not simply selecting hypromellose. Developers must control:

• Polymer substitution type
• Viscosity grade
• Polymer concentration
• Drug-to-polymer ratio
• Granulation endpoint
• Tablet porosity
• Compression force
• Coating weight
• Dissolution under fed and fasted conditions

A robust polymer platform can be reused across other highly soluble, high-dose drugs. That increases the strategic value of levetiracetam as a development product even when the product-level margin is limited.

Intravenous ready-to-use products

Hospitals may value premixed levetiracetam infusion bags because they reduce compounding steps and preparation errors. A ready-to-use product can compete on:

• Standardized concentration
• Shelf life
• Storage temperature
• Compatibility with automated dispensing systems
• Reduced pharmacy labor
• Lower manipulation risk
• Availability during emergency treatment

The main barriers are sterile manufacturing capacity, container-closure validation, extractables and leachables, and stability in the selected bag or vial system. The excipient system is relatively simple, but the packaging and manufacturing requirements are demanding.

Excipient supply and dual sourcing

Levetiracetam has high generic volume, making supply reliability important even where the excipient itself is not innovative. Commercial opportunities include qualified second sources for:

• Hypromellose
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Polyethylene glycol
• Pharmaceutical-grade flavors
• Polyols
• Preservatives
• Ready-to-use buffer systems

Suppliers with Drug Master Files, strong change-control systems, compendial compliance, low elemental impurity risk, and regional manufacturing redundancy can compete for generic and contract-manufacturing accounts.

What patents protect levetiracetam formulations?

The original levetiracetam compound and branded formulations are no longer protected by a commercially meaningful U.S. composition-of-matter exclusivity position. The principal U.S. compound patent associated with levetiracetam, U.S. Patent No. 4,696,933, expired after the branded product’s commercial exclusivity period.

Protection category	Current commercial position
Levetiracetam compound	Original U.S. protection expired
Immediate-release tablets	Broad generic competition
Oral solution	Broad generic competition; formulation differentiation remains possible
Intravenous injection	Generic competition with sterile-manufacturing barriers
Extended-release tablets	More formulation-sensitive than immediate release
New taste-masked or multiparticulate products	Potentially patentable if technically distinct
New device or packaging systems	Potentially patentable depending on structure and use

The strongest remaining patent opportunities are narrow formulation, delivery, manufacturing, or device claims. Potential claim areas include:

• Defined polymer ratios
• Specific dissolution profiles
• Taste-masked particles
• Multiparticulate sprinkle systems
• Feeding-tube-compatible formulations
• Concentrated solutions with specified stability
• Preservative-free multidose systems
• Ready-to-use intravenous containers
• Manufacturing processes that improve impurity control or content uniformity

A new patent must provide more than the substitution of one common excipient for another. Patentability and commercial defensibility improve when the formulation produces a measurable technical effect, such as improved taste scores, reduced degradation, altered pharmacokinetics, improved stability, or reduced dosing volume.

When does levetiracetam lose exclusivity in the United States?

Levetiracetam has already lost U.S. market exclusivity. FDA-approved generic immediate-release products entered the market after expiration of the relevant branded protections, and generic competition now covers tablets, oral solution, and injection.

Keppra XR also faces generic competition. The extended-release segment remains more technically demanding because the generic must match the reference release profile, but the loss of broad branded exclusivity limits the value of a conventional XR product without a distinct delivery or commercial advantage.

What is the Orange Book status of levetiracetam?

The FDA Orange Book identifies approved drug products and any applicable patent or exclusivity information submitted by applicants. Levetiracetam’s mature generic market means that the principal commercial question is usually not whether the active ingredient remains protected, but whether a particular product has a formulation, method-of-use, device, or regulatory exclusivity position.

For a new levetiracetam product, Orange Book strategy depends on the NDA pathway:

• An ANDA generally relies on the reference product and does not create broad new exclusivity.
• A 505(b)(2) application may support a differentiated formulation or route of administration.
• A new formulation can qualify for separate patent listings if the listed patents meet FDA requirements.
• Three-year exclusivity may be available for certain applications containing new clinical investigations essential to approval.
• Five-year new chemical entity exclusivity does not apply to a reformulation of an already approved active ingredient.

The Orange Book position should be reviewed product by product because patent listings can differ between immediate-release, extended-release, oral-liquid, and injectable products. [1]

Which companies are challenging levetiracetam exclusivity?

The U.S. market includes multiple generic manufacturers and authorized or branded-generic suppliers. Common competitive participants in levetiracetam include Teva, Mylan/Viatris, Lupin, Dr. Reddy’s Laboratories, Sun Pharmaceutical, Zydus, Aurobindo, Hikma, Amneal, and other FDA-approved manufacturers, depending on dosage form and market period.

The competitive structure is fragmented for immediate-release products and narrower for sterile injection and extended-release products. Generic entrants typically compete on:

• Contract price
• Supply continuity
• Form strength availability
• Hospital contracting
• Wholesaler coverage
• Formulary access
• Manufacturing reliability

Paragraph IV risk is most relevant when a new product relies on a patent listed for a specific extended-release formulation, device, or method of use. For ordinary immediate-release levetiracetam tablets, the commercial risk is primarily price erosion and supply competition rather than active patent litigation.

What FDA regulatory requirements apply to levetiracetam excipients?

FDA evaluates excipients through the finished product rather than granting blanket approval for an excipient in every formulation. Developers must establish that each excipient is appropriate at the proposed concentration, route, dosage form, and patient population.

Key regulatory considerations include:

• Inactive Ingredient Database precedent
• Compendial status
• Supplier qualification
• Residual solvents
• Elemental impurities
• Nitrosamine risk
• Microbial limits
• Preservative effectiveness
• Extractables and leachables
• Stability-indicating analytical methods
• Container-closure compatibility
• Pediatric acceptability for oral liquids
• Compatibility with enteral feeding tubes
• In-use stability after opening

The FDA Inactive Ingredient Database can support development when an excipient has prior use in the same route and dosage form. A new concentration, route, or patient population may still require additional justification. [2]

For oral liquids, the developer must control pH, viscosity, osmolality, microbial quality, preservative performance, and dosing-device accuracy. For extended-release tablets, comparative dissolution testing is central. For intravenous products, sterility, endotoxin, particulate matter, and container compatibility are critical.

How strong is the levetiracetam patent estate?

The patent estate is weak for conventional immediate-release products and stronger only for technically differentiated formulations.

Product strategy	Patent strength	Regulatory complexity	Commercial potential
Standard immediate-release tablet	Low	Low	Low to moderate
Standard oral solution	Low	Moderate	Moderate
Improved taste-masked liquid	Moderate	Moderate to high	Moderate to high
Sprinkle or multiparticulate product	Moderate to high	High	High in selected populations
Extended-release tablet	Moderate	High	Moderate
Preservative-free liquid	Moderate	Moderate	Moderate
Ready-to-use IV bag	Moderate	High	Moderate to high
New delivery device	Moderate to high	Moderate to high	Depends on channel

Patent strength depends on claim breadth, unexpected performance data, freedom-to-operate analysis, and the ability to prevent substitution with a different excipient system. Narrow claims covering a specific polymer grade or flavor combination may be easy to design around. Claims tied to measurable performance, particle structure, or device architecture are more defensible.

What generic launch risks exist for levetiracetam?

A new generic levetiracetam product faces several launch risks:

1. Price erosion: Immediate-release tablets are vulnerable to rapid price compression after multiple entrants.
2. Bioequivalence failure: Modified-release products are sensitive to formulation changes and dissolution variability.
3. Liquid acceptability: Poor taste can limit pharmacy substitution and patient persistence.
4. Manufacturing concentration: Sterile injection requires qualified facilities and validated processes.
5. Supply disruption: Excipient or API interruptions can affect hospital contracts.
6. Device mismatch: An inaccurate oral syringe can create dosing risk.
7. Regulatory change: Excipient changes may trigger additional stability or bioequivalence work.
8. Channel-specific competition: Retail, hospital, long-term care, and pediatric markets have different purchasing criteria.

The most attractive launch profile is usually a differentiated presentation with a clear operational or patient-use benefit, rather than another standard tablet.

What licensing deals and partnership opportunities exist?

Levetiracetam is no longer primarily a licensing opportunity for the active ingredient. Partnership value is more likely to arise from:

• Taste-masking technology licenses
• Pediatric formulation platforms
• Oral syringe and dosing-device partnerships
• Multiparticulate manufacturing
• Ready-to-use sterile packaging
• Contract development and manufacturing
• Regional generic commercialization
• Dual-source excipient supply agreements

A technology owner can improve deal economics by offering a package that includes formulation know-how, analytical methods, stability data, regulatory support, and manufacturing transfer. A standalone flavor system is less defensible than an integrated formulation platform with demonstrated patient-use advantages.

How does levetiracetam compare with competing antiepileptic drugs?

Levetiracetam competes with generic lamotrigine, valproate, carbamazepine, oxcarbazepine, phenytoin, topiramate, and lacosamide. Its formulation opportunity differs from these products.

Drug	Key formulation opportunity	Main excipient challenge
Levetiracetam	Pediatric liquid, XR, ready-to-use IV	Taste and release control
Lamotrigine	Chewable/dispersible tablets	Taste, dose escalation, stability
Valproate	Liquids, delayed-release, ER products	Irritation, taste, stability
Carbamazepine	Suspensions and controlled release	Crystal form and release control
Lacosamide	Oral liquid and IV products	Cost and hospital positioning
Phenytoin	Injection and suspension	Solubility and precipitation
Topiramate	Sprinkle capsules and liquids	Particle engineering and taste

Levetiracetam has an advantage in formulation simplicity for immediate-release products and injection. Its commercial weakness is the large number of generic competitors and limited ability to command a premium without a distinct presentation.

What geographic opportunities exist for levetiracetam formulations?

The United States and Europe are mature generic markets. Growth opportunities are more likely in selected emerging markets, hospital channels, and pediatric formulations.

Regional priorities include:

• U.S.: 505(b)(2) reformulations, hospital injection products, specialty generics
• European Union: pediatric-friendly products, multilingual labeling, unit-dose formats
• Japan: age-appropriate formulations and local regulatory bridging
• India: high-volume generics and contract manufacturing
• Latin America: stable oral liquids and affordable pediatric presentations
• Middle East and Africa: heat-stable products and supply reliability

Excipient selection must account for climate-zone stability, local flavor preferences, preservative requirements, and packaging availability. A formulation optimized for U.S. retail pharmacies may not be optimal for tropical distribution or hospital procurement.

What manufacturing and intellectual-property barriers affect levetiracetam?

Manufacturing barriers are highest for sterile injection and extended-release products. The principal technical barriers include:

• Consistent polymer hydration in XR tablets
• Uniform distribution of low-dose excipients
• Control of liquid microbial quality
• Flavor and preservative stability
• Low-particulate sterile filling
• Container-closure integrity
• Feeding-tube compatibility
• Scale-up without changing dissolution or viscosity

Intellectual-property barriers are more manageable for standard products. A developer should conduct freedom-to-operate review across:

• Formulation patents
• Taste-masking patents
• Multiparticulate and sprinkle patents
• Modified-release patents
• Dosing-device patents
• Packaging patents
• Manufacturing-process patents
• Method-of-use claims involving specific patient populations

Key Takeaways

• Levetiracetam is a mature generic drug with no meaningful broad U.S. compound exclusivity remaining.
• Standard immediate-release tablets offer limited formulation differentiation and face substantial price competition.
• Oral liquids provide the clearest excipient-led opportunity through taste masking, lower dosing volume, preservative alternatives, and pediatric usability.
• Extended-release products require tight control of hypromellose or other polymer systems and remain more difficult to develop than immediate-release tablets.
• Ready-to-use intravenous products can create hospital value through reduced preparation and improved workflow.
• Patent opportunities are strongest for technically defined taste-masked, multiparticulate, device-enabled, or sterile presentations.
• Excipient suppliers can compete through qualified dual sourcing, regulatory documentation, impurity control, and manufacturing consistency.
• A commercially strong levetiracetam product should combine a measurable patient or operational benefit with a defensible formulation or device claim.

Frequently Asked Questions

Is levetiracetam oral solution a good formulation opportunity?

Yes. Oral solution is the most accessible opportunity because taste, dosing volume, preservative choice, and pediatric administration directly affect product use. A differentiated product needs a measurable benefit beyond a new flavor.

Can a new levetiracetam excipient combination receive patent protection?

Yes, but ordinary excipient substitution is unlikely to create a strong estate. Patentability improves when the combination produces unexpected taste, stability, release, bioavailability, or administration results.

Which levetiracetam dosage form has the highest technical barrier?

Intravenous injection and extended-release tablets have the highest technical barriers. Injection requires sterile manufacturing and container validation, while extended release requires tight control of dissolution and pharmacokinetic performance.

Is a preservative-free levetiracetam liquid commercially viable?

It can be viable in unit-dose or carefully designed multidose packaging. The commercial case depends on manufacturing cost, in-use stability, microbial protection, and whether the target market values preservative avoidance.

Can levetiracetam be reformulated for feeding-tube administration?

Yes. A product can be designed for enteral administration, but development must address dose recovery, tube adsorption, clogging, dispersion, viscosity, compatibility with feeding formulas, and post-opening stability.

References

1. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2025). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (2024). Keppra levetiracetam prescribing information. UCB, Inc. https://www.accessdata.fda.gov

4. DailyMed. (2025). Levetiracetam drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

5. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry. https://www.fda.gov

6. U.S. Food and Drug Administration. (2019). Quality considerations for chewable tablets. Guidance for Industry. https://www.fda.gov

7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

8. U.S. Patent No. 4,696,933. (1987). Levetiracetam and related compounds. United States Patent and Trademark Office.